Vinings Holdings

Vinings Holdings was a U.S. holding company that conducted its healthcare operations through Coeptis Pharmaceuticals and later rebranded as Coeptis Therapeutics in July 2021. Around the time of the rebrand, the company described a mixed portfolio consisting of two clinical-stage drug candidates, two approved cardiovascular/pain products, and option-based access to cell therapy and diagnostic assets targeting CD38-related cancers. Following subsequent corporate transactions, the Vinings Holdings name ceased to be the primary operating brand and the business evolved into Coeptis Therapeutics Holdings, a Nasdaq-listed biopharmaceutical company focused on cell therapy platforms. For entity-matching purposes, "Vinings Holdings" is an exact historical company name, but it is not the current active operating name of the business.